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A B S T R A C T
Vancomycin-resistant enterococci (VRE) are important nosocomial pathogens. Invasive VRE infections are dif-
ﬁcult to treat since common therapeutic options including ampicillin and glycopeptides often fail. In vitro, most
VRE remain susceptible to last-resort antibiotics such as linezolid, tigecycline and daptomycin. However, neither
tigecycline nor linezolid act in a bactericidal manner, and daptomycin has proven activity only at high dosages
licensed for treating enterococcal endocarditis. Despite these pharmacological and therapeutic limitations, re-
ports on resistance to these last-resort drugs in VRE, and enterococci in general, have increased in recent years.
In this review, we brieﬂy recapitulate the current knowledge on the mode of action as well as the known and
novel mechanisms of resistance and describe surveillance data on resistance to linezolid, tigecycline and dap-
tomycin in enterococci. In addition, we also suggest a common nomenclature for designating enterococci and
VRE with resistances to these important last-resort antibiotics.
Introduction
Enterococci are important commensal bacteria residing in the in-
testines of humans and many other animals, including invertebrates.
They are known as early colonizers of neonates and constitute a sub-
stantial part of the healthy intestinal microbiota of adults. Due to their
beneﬁcial impact on gut health, enterococcal mixtures have been li-
censed as probiotics. Various enterococci are used for food fermentation
and preservation (Franz et al., 2011) due to their abilities to produce
highly eﬀective bacteriocins active against food-borne pathogens such
as Listeria monocytogenes. The two species Enterococcus faecium and
Enterococcus faecalis have been recognized for decades as major noso-
comial pathogens in humans. Moreover, E. faecalis is occasionally im-
plicated in community-associated infections such as urinary tract in-
fections and endocarditis.
Members of the genus Enterococcus are known to be versatile
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microorganisms capable of surviving under harsh conditions and
quickly adapting to a changing environment. Their biological con-
stitution allows for a high rate of DNA recombination against a back-
ground level of mutation, which then facilitates survival under varying
situations at the population level. Within the E. faecium species, fre-
quent DNA exchange associated with niche separation and niche
adaptation have shaped a subpopulation, called clade A1, that has
clearly adapted to the hospital setting (Lebreton et al., 2013). Diﬀerent
models exist that describe the origin of these hospital-associated E.
faecium lineages (Lebreton et al., 2013; Numminen et al., 2016); how-
ever, it is still under debate as to whether today’s hospital-associated E.
faecium strains originated from commensal strains in humans and ani-
mals or, in fact, evolved directly from livestock animals (Lebreton et al.,
2013; Raven et al., 2016; Willems et al., 2012). Niche adaptation and
host speciation is much less pronounced in E. faecalis, although a
number of clonal lineages exhibit an association with hospitals, to a
certain extent (CC2 and CC9; (Kuch et al., 2012; Numminen et al.,
2016; Tedim et al., 2015).
Currently, E. faecium and E. faecalis rank as the second and third
most important nosocomial pathogens worldwide (Kolonen et al., 2017;
Mendes et al., 2016a; Weisser et al., 2017; Zhang et al., 2017). Even
though the pathogenicity of these species is controversial, enterococcci
can cause life-threatening infections in humans, mainly among elderly,
multimorbid and/or immunocompromised patients (Arias and Murray,
2012; Murray, 1990). A wide armamentarium of natural resistance in
this genus prevents a number of frequently used modern drugs such as
cephalosporins and ﬂuoroquinolones from being eﬀective against en-
terococcal infections (Arias and Murray, 2012; Murray, 1990). Whereas
ampicillin and glycopeptides are important ﬁrst-line therapeutics, al-
most all hospital-associated strains of E. faecium have acquired ampi-
cillin resistance (Lester et al., 2008; Top et al., 2007; Weisser et al.,
2012). Moreover, since the mid-1980s, enterococci have garnered in-
creased medical and public attention when vancomycin resistance ﬁrst
appeared in clinical isolates of E. faecium and E. faecalis (vancomycin-
resistant enterococci; VRE) (Johnson et al., 1990; Uttley et al., 1989).
Increased prevalence of ampicillin and vancomycin resistance, mostly
among hospital-associated E. faecium isolates, has led to the therapeutic
dilemma of multidrug-resistant (MDR) pathogens. Hence, these isolates,
along with other superbugs such as Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and En-
terobacter species, have been dubbed the “ESKAPE” pathogens (Boucher
et al., 2009). Several reports and reviews have assessed rates of VRE
among clinical enterococcal isolates and in speciﬁc clinical indications
(such as bloodstream infections) (Adams et al., 2016; Akpaka et al.,
2017; Simner et al., 2015; Weisser et al., 2017; Werner et al., 2008a). In
general, the number of infections caused by enterococcal isolates,
mainly E. faecium, and of those that are vancomycin resistant, has in-
creased in many industrialized countries all over the world. Conse-
quently, VRE are also considered a signiﬁcant antibiotic resistance
threat, leading to in excess of 20,000 drug-resistant Enterococcus in-
fections and approximately 1300 deaths due to VRE in the US each year
(CDC 2013, https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-
508.pdf). Through participation in the European Antimicrobial Re-
sistance Surveillance Network (EARS-Net), coordinated by the Eur-
opean Center for Disease Prevention & Control (ECDC), many European
countries have experienced an increased proportion of ampicillin re-
sistant enterococci in invasive infections, mainly E. faecium, which are
also resistant to vancomycin (Tedim et al., 2017). However, the Eur-
opean-wide trend of VRE causing systemic infections has remained
inconsistent (https://ecdc.europa.eu/sites/portal/ﬁles/documents/
antibiotics-EARS-Net-summary-2016_0.pdf). Ireland has been re-
porting the highest rate of vancomycin resistance among E. faecium
bloodstream isolates in Europe in the last 10 years. Since 2012, more
than 40% of E. faecium bloodstream isolates have been identiﬁed as
vancomycin-resistant.
In the hospital setting, most VRE are also resistant to ﬁrst line
antibiotics (ampicillin, quinolones) with high MIC values. Furthermore,
E. faecium and E. faecalis are often high-level resistant to aminoglyco-
sides (HLAR). Hence, only a few therapeutic options, including ox-
azolidinones (linezolid, tedizolid), novel tetracyclines (tigecycline) and
lipopeptides (daptomycin) remain to treat infections with multidrug-
resistant VRE (Barber et al., 2015; Mutters et al., 2015; Whang et al.,
2013; Zhao et al., 2016). The increasing prevalence of VRE in many
countries and health-care settings, the expanded use of such last-resort
antibiotics, and the ability of enterococci to easily acquire novel DNA
fragments encoding resistance determinants currently enhance the se-
lective pressure for developing resistance to these compounds. The
genetic constitution of enterococci with a high recombination rate and
the frequent occurrence of mobile genetic elements within the genome,
as well as their natural habitat, predestine enterococci as a suitable
indicator for novel emerging resistance phenotypes. We herein aim to
summarize the general knowledge on non-susceptibility to last-resort
antibiotics in Enterococcus spp. with a special focus on linezolid, tige-
cycline and daptomycin resistance. There are international surveillance
systems that monitor the in vitro activities of these antimicrobial com-
pounds, such as T.E.S.T. (Tigecycline Evaluation and Surveillance Trial)
(Marco and Dowzicky, 2016; Vega and Dowzicky, 2017). They further
serve as a basis for comprehensive databases from which resistance
development can be analyzed retrospectively on a global scale (ATLAS,
Antimicrobial Testing Leadership And Surveillance; supported by
Pﬁzer). For the vast majority of the European countries, a generally low
prevalence (< 1%) of isolates resistant to last-resort antibiotics has
been noted (ATLAS database; https://atlas-surveillance.com). For this
review article, we have comprehensively compared susceptibility data
on enterococci with regard to linezolid, tigecycline and daptomycin and
have summarized recent advances in studying the underlying resistance
mechanisms in order to propose a common nomenclature for VRE with
resistance to last-resort antibiotics.
Vancomycin resistance in Enterococcus spp.
Although this is not in the main focus of this report, we provide a
short overview of the current state of knowledge of the diﬀerent gen-
otypes of vancomycin resistance in enterococci. At present, eight types
(VanA to VanN) of vancomycin resistance are known, named according
to its ligase gene (vanA to vanN). In addition to the ligase gene, two
other genes encoding the sensor (VanS) and response regulator (VanR)
are essential to confer the corresponding phenotype. Glycopeptide an-
tibiotics bind to the N-terminal D-Ala-D-Ala residue present in dis-
accharide-pentapeptide cell wall precursors. The interplay between
several expressed resistance genes allows for the downregulation of
housekeeping cell wall precursor synthesis and the production of an
alternative pentapeptide (the so-called pentadepsipeptide) side chain
ending with D-lactate (e.g., VanA, VanB) or D-serine (e.g., VanG)
(Courvalin, 2006). This alternative ending exhibits an up to 1,000-fold
lower binding capacity to vancomycin (in case of D-Ala-D-Lac), which
results in clinical resistance. The vanA and vanB resistance genotypes
are by far the most frequently found variants in clinical E. faecium and
E. faecalis isolates worldwide. The vanA gene cluster (carried by
transposon Tn1546) is mainly plasmid-located, whereas the vanB gene
cluster (carried by members of the integrative conjugative elements
Tn1549-Tn5382) is usually present on the bacterial chromosome. For
more details, the reader is referred to a number of review articles
dedicated to this topic (Courvalin, 2006; Hegstad et al., 2010; Werner
et al., 2013).
A speciﬁc variant of VRE is represented by vancomycin-variable
enterococci (VVE); these strains were noticed only very recently. VVE
are vancomycin-susceptible enterococci with a vanA genotype (VVE-S),
which can become resistant to vancomycin (VVE-R) upon exposure to
vancomycin or teicoplanin (Coburn et al., 2014; Sivertsen et al., 2016).
Development of vancomycin resistance in VVE-S can arise from dif-
ferent mechanisms and result in the expression of vanHAX genes, in
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either a restored vancomycin-inducible fashion (Sivertsen et al., 2016)
or constitutively (Thaker et al., 2015). Outbreaks of VVE have been
reported in Canada (Szakacs et al., 2014), Norway (Sivertsen et al.,
2016) and Denmark (Hansen et al., 2018). Sporadic isolates of VVE
have also been reported in other European countries (Jung et al., 2014;
Loens et al., 2016; Sivertsen et al., 2017). Most of the reported VVE
isolates have been E. faecium, but this phenomenon can also occur in E.
faecalis (Sivertsen et al., 2016). The overall prevalence of VVE-S is
unknown. Since the expression of vancomycin resistance genes is
turned oﬀ in VVE-S, they are not easily detected with phenotypic
methods. However, since vancomycin and teicoplanin exposure over
days promote the development of resistance, VVE have caused treat-
ment failure and could be considered an emerging threat (Downing
et al., 2015; Sivertsen et al., 2016).
Last-resort antimicrobials to treat VRE infections
Oxazolidinones
Linezolid: mode of action
Linezolid (LZD) is the ﬁrst representative of the oxazolidinones that
received approval for clinical practice by the US Food and Drug
Administration (FDA) in 2000 (and later by the European Medicines
Agency, EMA). This bacteriostatic antibiotic exhibits activity against a
broad range of Gram-positive bacteria, including Methicillin-resistant
Staphylococcus aureus (MRSA), and has received licensing for the
treatment of nosocomial pneumonia, complicated or uncomplicated
skin and soft tissue infections (SSTIs) and for infections caused by VRE
(Brickner et al., 2008; Plosker and Figgitt, 2005). Although it adds to
the substances that inhibit bacterial protein synthesis, cross-resistance
triggered by antibiotics with proximal target sites have not been de-
scribed, which is most likely due to the distinct mechanism of LZD
action (Fines and Leclercq, 2000; Kloss et al., 1999). By targeting
bacterial protein translation, oxazolidinones prevent the formation of
the initiation complex by binding to domain V of the 23S rRNA (Swaney
et al., 1998; Wilson et al., 2008). Nevertheless, during a compassionate
use program and following implementation in clinical daily routine, the
detection of LZD-resistant bacteria has been reported, including those
that emerged during LZD therapy (Bassetti et al., 2003; Birmingham
et al., 2003; Krull et al., 2016; Seedat et al., 2006). LZD is the only
antibiotic of last resort discussed in this overview that can be given also
orally in addition to an intravenous application suggesting a wider se-
lective pressure, for instance, also on bacteria with an intestinal re-
servoir.
Linezolid: mechanisms of resistance
Resistance to LZD (MIC > 4mg/L; www.eucast.org) can be medi-
ated by either mutational mechanisms or by gene acquisition (sum-
marized in Table 1). The most common resistance mechanism in en-
terococci is based on a G-to-T conversion at position 2576 (according to
E. coli K-12 numbering) within the genes encoding for 23S ribosomal
RNAs (Klare et al., 2015; Mendes et al., 2014; Pfaller et al., 2017b). The
LZD MIC increases with the copy number of mutated 23S rDNA alleles
and LZD resistance in enterococcal isolates is rapidly selected under
LZD therapy (Bassetti et al., 2003; Marshall et al., 2002; Seedat et al.,
2006). The initial 23S rDNA mutation is a crucial step in resistance
progression, as additional 23S rDNA mutation sites in the genome are
most likely generated by recombination rather than by individual point
mutations (Marshall et al., 2002). The classical G2576 T mutations also
seem to determine resistance to tedizolid, the second clinically avail-
able oxazolidinone (Klupp et al., 2016). Acquired resistance-de-
termining mutations appear to be stable, as 40 to 50 daily passages of a
clinical LZD-resistant E. faecium isolates in non-selective media (ca. 300
bacterial generations) were not suﬃcient to revert resistance associated
with heterozygous G2576 T mutations (Freitas et al., 2016; Klare et al.,
2015). For one of these experiments, E. faecium strains (n=3) were Ta
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isolated from a Portuguese patient taking linezolid for 61 days, who
developed three variants of the same LZD-resistant clone presenting
diﬀerent antibiotic resistance and virulence proﬁles. Yet another me-
chanism based on nucleotide mutations has been described for genes
encoding for ribosomal proteins. Here, mutations in rplC (L3) and rplD
(L4) are predominantly linked to LZD resistance in enterococci that lack
G2576 T mutations and that do not express the multidrug resistance
gene cfr (Chen et al., 2013).
Cfr was ﬁrst isolated from Staphylococcus sciuri of animal origin and
soon received enormous attention, as it is capable of conferring re-
sistance to at least ﬁve classes of antibiotics, including linezolid (but not
tedizolid); it has been detected in various bacterial species and genera
(Locke et al., 2014; Long et al., 2006; Schwarz et al., 2000; Shen et al.,
2013). The resistance phenotype mediated by the Cfr methyltransferase
is commonly referred to as PhLOPSA, an acronym for resistance to the
antibacterial agents phenicol, lincosamide, oxazolidinone, pleur-
omutilin and streptogramin A (Long et al., 2006). Most importantly, the
transfer of plasmid-borne cfr has been demonstrated to occur even
across bacterial species and genera (Bender et al., 2016; Caﬁni et al.,
2016).
Regarding enterococci, cfr was ﬁrst reported from E. faecalis of an-
imal origin (Liu et al., 2012). Follow-up studies in enterococci identi-
ﬁed several distinct conjugative plasmids that harbored the multidrug
resistance gene (Liu et al., 2013, 2012). Transfer of the cfr-harboring
plasmids was demonstrated and the wildtype cfr (staphylococci
homolog) and derivatives thereof, named cfr(B) and cfr(B) variants,
located on plasmids or within the bacterial chromosome emerged in
Enterococcus spp. from animal and human samples alike (Bender et al.,
2016; Deshpande et al., 2015; Diaz et al., 2012; Liu et al., 2014a, 2013;
Patel et al., 2013). It is worth noting that E. faecium isolates containing
the cfr gene are increasingly observed (Cercenado et al., 2010).
Nevertheless, the contribution of cfr and cfr(B) variants to elevated LZD
MICs in Enterococcus spp. is still under debate. It has been shown that,
probably due to yet unknown strain-speciﬁc reasons, Cfr and Cfr(B)
variants fail to demonstrate LZD resistance and the entire PhLOPSA
phenotype in enterococci (Bender et al., 2016; Liu et al., 2014b).
Further studies on enterococci with a silent cfr gene, but exhibiting
LZD resistance, have demonstrated a role for a second LZD (and tedi-
zolid) resistance determinant, the oxazolidinone and phenicol trans-
ferable resistance A (OptrA) (Brenciani et al., 2016; Wang et al., 2015).
First detected in E. faecalis of human origin, further studies have been
published reporting optrA in isolates of E. faecalis and E. faecium and
most recently also in S. aureus, S. sciuri and Streptococcus suis (Cai et al.,
2016; Cui et al., 2016; Guo et al., 2018; He et al., 2016; Huang et al.,
2017; Li et al., 2016). Surveillance studies from China have shown that
optrA is detected more frequently in enterococci from food-producing
animals than in humans (Wang et al., 2015). OptrA encodes for an ATP-
binding cassette (ABC)-F protein and mediates resistance through target
protection (Sharkey and O’Neill, 2018). Releasing ribosome-targeted
antibiotics such as phenicols, compounds commonly used in the animal
production, highlights the relevance of selected antibiotic usage in
animal husbandry for the emergence of bacteria carrying this resistance
determinant (Wang et al., 2015). Moreover, reports from animals raised
in Korea, Tunisia and Colombia or residual wastewaters in Tunisia
where E. faecalis isolates with optrA have been described pointed to-
wards an important animal reservoir as well as the possibility of on-
going environmental dissemination of this resistance gene [(Cavaco
et al., 2017; Tamang et al., 2017) A.R.F. and L.P., unpublished data].
Recently, the analysis of 26 E. faecalis isolates from humans with LZD
MIC > 4mg/L obtained from the SENTRY program (see above) re-
vealed a high prevalence (53.5%) of optrA-positive E. faecalis from
humans; however, not all of these isolates exhibited LZD resistance
(Mendes et al., 2016b). Congruently, the German National Reference
Center (NRC) for staphylococci and enterococci at the Robert Koch
Institute (RKI) have observed an increase in optrA-positive and LZD-
resistant clinical (human) E. faecalis from 2007 to 2016, with 90.9% of
all LZD-resistant E. faecalis (n= 35) isolates being optrA-positive in
2016 (Bender et al., 2018). Moreover, all LZD-resistant E. faecalis iso-
lates reported to the Norwegian National Advisory Unit on Detection of
Antimicrobial Resistance since December 2015 harbored optrA (Heg-
stad et al., unpublished). In a study on Polish LZD-resistant enterococci
(Gawryszewska et al., 2017), two E. faecalis strains were positive for
optrA with the resistance determinant located on a transferable plasmid
identical to pE394, initially reported in China (Wang et al., 2015). With
respect to the One Health dimension, optrA has been reported from an
ST22 E. faecium strain isolated from imported turkey meat and an ST22
E. faecalis strain isolated from Danish veal meat (Cavaco et al., 2017).
Likewise, an ST16 E. faecalis isolate with optrA has been reported in a
Danish patient (Vorobieva et al., 2017).
Exceeding what is known for cfr, a high diversity of optrA nucleotide
sequences and a plethora of variable genetic environments embedding
the resistance gene in either the chromosome or on diverse plasmids
and/or within transposon structures (Tn554, Tn558, ﬂanked by IS1216
or similar IS elements) have been reported (Bender et al., 2018; He
et al., 2016; Huang et al., 2017; Mendes et al., 2016b). Hence, rapid
spread of the resistance locus is conceivable with the possibility of
global distribution being underestimated to date.
Recently, another member of the ABC-F protein subfamily, PoxtA,
has been discovered in MRSA of clinical origin, clostridia and en-
terococci, exerting its protective eﬀect against phenicols, ox-
azolidinones and tetracyclines (Antonelli et al., 2018). The prevalence
of poxtA amongst the enterococcal population is under current in-
vestigation.
Although insuﬃciently studied, cell wall thickness and bioﬁlm
formation were discussed as putative alternative resistance pathways to
acquire LZD resistance (Tian et al., 2014); however, the authors had no
knowledge of optrA or poxtA at the time when the article was published
and thus did not screen for this particular resistance loci. Also, it re-
mains to be determined as to how the combination of determinants
and/or genetic background with respect to species impacts LZD MICs. A
ﬁrst report by Mendes and co-workers and as also observed by the NRC
for Staphylococci and Enterococci in Germany and the Norwegian
National Advisory Unit on Detection of Antimicrobial Resistance de-
monstrated that the frequency of particular LZD resistance mechanisms
seems to diﬀer between E. faecalis and E. faecium. A tendency of 23S
rDNA mutation being mostly common in E. faecium and optrA dom-
inating in E. faecalis was generally observed (Mendes et al., 2016b).
A plethora of LZD resistance mechanisms already exists in en-
terococci, and novel ones have emerged relatively rapidly. Hence, it is
conceivable that additional factors might be discovered with the po-
tential to equally contribute to infections of and outbreaks caused by
linezolid-resistant enterococci (LRE). In fact, LRE without any of the
currently known resistance mechanisms have been reported, both as-
sociated with infection and colonization (A.R.F. and L.P., pers. com-
munication; J.K.B. and G.W.; pers. communication; K.H. pers. com-
munication). Recently, Hua et al. demonstrated diﬀerential expression
of genes related to eﬄux pumps and or bioﬁlm formation in strains
showing low-level resistance to LZD and lacking known resistance
mechanisms using a whole transcriptomic approach (Hua et al., 2018).
Alarmingly, gene acquisition or mutational changes do not seem to
impact bacterial ﬁtness, as Hegstad and colleagues noticed the persis-
tence of an ST117 LZD-resistant E. faecium clone in a Scandinavian
hospital for over one year (Hegstad et al., 2014). Likewise, acquisition
of an optrA-plasmid by E. faecalis did not aﬀect the growth rates of the
transconjugant compared to the plasmid-free recipient (Gawryszewska
et al., 2017).
Thus, prudent use of LZD is indispensable to prevent the emergence
and dissemination of multidrug-resistant strains. Again, it must be
stressed that the occurrence of enterococci susceptible to linezolid but
carrying silent cfr and/or optrA might hamper their identiﬁcation in a
clinical setting (Brenciani et al., 2016). The potential to disseminate a
highly promiscuous resistance locus to other bacteria imposes an
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unpredictable risk to diﬀerent sectors.
Linezolid: resistance surveillance data
Infections due to LRE and their nosocomial spread have been de-
scribed in several case reports and outbreak investigations for both
vancomycin-resistant and vancomycin-susceptible E. faecium and E.
faecalis (Gomez-Gil et al., 2009; Gonzales et al., 2001; Hegstad et al.,
2014; Herrero et al., 2002; Ntokou et al., 2012; O’Driscoll et al., 2015;
Rahim et al., 2003). LZD exposure, prolonged antibiotic treatment,
hospitalization in a hematological ward, immunodeﬁciency, prior sur-
gery and patient-to-patient transmission have been identiﬁed as risk
factors to acquire LRE infections (Hayakawa et al., 2012; Kainer et al.,
2007; Scheetz et al., 2008; Souli et al., 2009). However, LZD resistance
does not necessarily only emerge upon LZD therapy (Mutters et al.,
2015).
Several national and international programs exist that started to
monitor LZD resistance development in the early 2000s. The SENTRY
Antimicrobial Surveillance Program, the Linezolid Experience and
Accurate Determination of Resistance (LEADER) initiative, ZAAPS
(Zyvox® Annual Appraisal of Potency and Spectrum) and T.E.S.T. con-
cordantly report a sustained high potency of LZD against the entire
spectrum of tested bacteria with very low rates of resistance develop-
ment over the last two decades (Flamm et al., 2016; Mendes et al.,
2016b, c; Mutnick et al., 2003; Pfaller et al., 2017a, b; Streit et al.,
2015). As for other Gram-positive bacteria, the general prevalence of
LRE still remains below 1%. It is also worth noting that no MIC creep
was observed amongst the isolates tested (Mendes et al., 2016c; Streit
et al., 2015). In a very recent review, enterococcal data from the US
LEADER and the global ZAAPS studies were summarized, again con-
ﬁrming the overall low prevalence of< 1% LZD resistance among
clinical Enterococcus spp. (Bi et al., 2017). The presence of common
resistance mechanisms was also analyzed, demonstrating the presence
of cfr in 4.7% of linezolid-resistant E. faecalis and in 4.8% of linezolid-
resistant E. faecium isolates. Altogether, 32 cases of optrA-positive en-
terococci were found.
Specialized reference laboratories throughout Europe have reported
a greater recognition of LRE. However, diﬀerences in resistance rates
might also depend on the species analyzed; for instance, a recent report
from China described that the occurrence of LZD non-susceptibility was
greater in E. faecalis compared to E. faecium (Tian et al., 2014).
In Germany, the national resistance surveillance scheme ARS
(https://ars.rki.de) has not observed any trend for linezolid resistance
among clinical E. faecalis or E. faecium isolates in recent years (< 1%).
However, the NRC recognized an increased frequency of LRE from<
1% in 2008 to> 9% in 2014 among all strains received annually for
subsequent strain characterization on a voluntary basis (Klare et al.,
2015).
Since the ﬁrst ﬁnding of LZD-resistant E. faecalis in 2012 (Thilesen
et al., 2014), only 20 LRE have been reported in Norway up to January
2, 2017 (https://unn.no/fag-og-forskning/k-res/betydelig-okt-
forekomst-av-linezolidresistente-enterokokker-i-2016-i-norge). Half of
these isolates were found in 2016, representing a signiﬁcant increase in
prevalence compared to previous years.
In Denmark, LRE have not been send to the antimicrobial reference
laboratory on a routine basis. However, during 2016, 14 LZD-resistant
E. faecalis (1.3%) and 27 LZD-resistant E. faecium (4.2%) were detected
from Rigshospitalet, in the capital region in Denmark (DANMAP 2016).
In the ﬁrst nine months of 2017, the incidence of LZD-resistant E. fae-
calis was reduced at Rigshospitalet to 0.5%, and that of LZD-resistant E.
faecium to 1.7%. This correlated with a reduction program for linezolid
usage at Rigshospitalet (J. D. Knudsen, pers. communication). In 2017,
two other Copenhagen hospitals had three isolates of LZD-resistant E.
faecium (0.1%) (H.W., pers. communication).
In Spain, an E. faecalis clinical isolate was the ﬁrst identiﬁed LRE in
2003 (Sanchez-Gomez et al., 2006). Since then, LRE, either E. faecalis or
E. faecium, have been detected in diﬀerent hospitals, mostly associated
with the use of this antibiotic in neutropenic patients (Alonso et al.,
2014; Sanchez-Diaz et al., 2014), eventually causing nosocomial out-
breaks (Gomez-Gil et al., 2009). Data from T.E.S.T. for tigecycline and
comparator compounds in Spain, which included isolates from 27
centers obtained from 2004 to 2014 (Marco and Dowzicky, 2016), re-
ﬂected linezolid resistance of 0.1% for E. faecalis (MIC90= 2; range
0.5–8mg/L) and 0.6% for E. faecium (MIC90= 2, range 0.5–16mg/L,).
Another collaborative study performed in Spain from 2015, including
data from 23,907 patients in 200 intensive care units as part of a
strategic program to reduce the risk of selection and spread of antibiotic
resistance in this country (Plan Nacional de resistencias a los anti-
bióticos, Programa PRAM, http://www.resistenciaantibioticos.es),
documented the occurrence of resistance to linezolid in 1.5% of E.
faecalis and 3.3% of E. faecium strains (Palomar et al., unpublished
data). Finally, the ﬁrst phenotypically LZD-resistant E. faecalis strain in
wild animals was documented in Spain; however, LZD resistance was
not conﬁrmed by a second, independent method (Navarro-Gonzalez
et al., 2013).
When analyzing T.E.S.T. data, no LRE were detected in Italy be-
tween 2012 and 2014 (Stefani and Dowzicky, 2016). The international
ZAAPS program assessing LZD resistance rates in 32 countries reported
in 2015 a single Italian E. faecium isolate with a conﬁrmed resistance
phenotype and a known G2756 T mutation (see below) (Pfaller et al.,
2017a). The national Italian Surveillance system AR-ISS has reported,
amongst others, linezolid resistance in isolates from bloodstream in-
fections. Linezolid resistance was detected in 0.6% (n=9/1,582) of E.
faecalis strains in 2015 and 0.3% (n= 5/1,579) in 2016 and in 0.4%
(n= 3/745) of E. faecium strains in 2015 and 1.1% (n=10/930) in
2016.
Poland obtained the ﬁrst LZD-resistant isolate of E. faecium as early
as in 2003 (Krawczyk et al., 2004). Since 2012, the National Reference
Center for Susceptibility Testing (NRCST) has witnessed both increasing
numbers of strains that were received by the NRCST as well as centers
that reported the occurrence of LRE. An analysis performed on 50
isolates in the period from 2008 to 2015 revealed the predominance of
hospital-associated E. faecium (82%); LZD-resistant E. faecalis and a
single isolate of E. avium were identiﬁed as well (Gawryszewska et al.,
2017). In that study, the G2576 T mutation was the most prevalent
mechanism of resistance, but isolates with optrA were also observed.
Out of 3,974 enterococcal clinical isolates sent to the French NRC
from 2006 to 2016, only 9 (0.2%) were resistant to linezolid
(MIC > 4mg/L; V.C. unpublished data). The ﬁrst isolate (found in
2010) possessed ribosomal mutations, whereas the more recent isolates
(one in 2013, one in 2014, two in 2015 and four in 2016) harbored the
plasmid-mediated optrA gene. Five strains isolated before 2016 were all
vanA-positive E. faecium, whereas strains isolated in 2016 were all
susceptible to vancomycin (one E. faecium and three E. faecalis).
In Ireland, LZD resistance in E. faecium blood culture isolates was
reported for the ﬁrst time in 2004, when four of 78 E. faecium isolates
tested against LZD were reported as being resistant (5.2%). In sub-
sequent years (2005–2016), LZD resistance continued to be reported
from blood culture isolates. Overall, among 4073 isolates tested against
LZD from 2002 to 2016, 75 were found to be resistant to LZD (1.8%). Of
3100 E. faecalis isolates tested against LZD between 2002 and 2016, 40
were found to be resistant (1.0%). LZD resistance in VRE-E. faecium
isolates from sites other than the bloodstream, along with outbreaks of
LZD-resistant VRE-E. faecium in tertiary hospitals, have also been re-
ported in Ireland since 2012. Surveillance data in one institution
showed an increase in LZD resistance in VRE-E. faecium from four iso-
lates in 2015 to 16 isolates in 2016 from both clinical and screening
specimens. The international ZAAPS program reported an Irish E. fae-
calis isolate from 2015 with LZD resistance and an optrA gene (Pfaller
et al., 2017a).
In Portugal, available data from three major hospitals in the north
and south of the country from 2009 to 2016 showed the occurrence of
35 Enterococcus spp. with LZD resistance. In each hospital, the incidence
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of linezolid resistance was below 1% (L.P., pers. communication). Data
from T.E.S.T., including 400 isolates from four Portuguese centers
collected from 2004 to 2016, conﬁrmed the very low incidence of
Enterococcus spp. resistant to LZD. Some of those isolates were also co-
resistant to vancomycin or tigecycline. LRE (n=7) and enterococci
with intermediate resistance (n=10; according to the Clinical &
Laboratory Standards Institute criteria) were identiﬁed among 14
sampled hospital wastewaters (Santos Arronches, 2014).
Besides the occurrence of LZD-resistant enterococci in hospitals,
their occurrence in other sources and habitats is of special concern.
Recent reports from the European Food Safety Authority (EFSA), pub-
lished together with the ECDC, indicated the presence of LZD resistance
in enterococcal indicator isolates (i.e., non-selective screening) col-
lected in 2012 and 2013 from food, especially from bovine and broiler
samples, but also from pigs and cattle. The samples originated from
various European countries including the Netherlands, France, Croatia,
Belgium and Spain (http://ecdc.europa.eu/en/publications/
Publications/antimicrobial-resistance-zoonotic-bacteria-humans-
animals-food-EU-summary-report-2013.pdf; last access 30/10/2018).
Tigecycline
Tigecycline: mode of action
Tigecycline (TGC) is the ﬁrst member of the class of glycylcyclines
(Pankey, 2005). Structurally, it is a derivative of minocycline with a
bulky ter-butyl-glycylamido side chain at the position 9 of the D ring
(Thaker et al., 2010). It exerts bacteriostatic activity against a broad
range of bacterial pathogens, including Gram-positive and Gram-ne-
gative bacteria, anaerobes and atypical organisms (Pankey, 2005; Stein
and Babinchak, 2013). It is currently approved for the treatment of
complicated SSTIs and complicated intra-abdominal infections (2005),
as well as community-acquired bacterial pneumonia (2008) (Stein and
Babinchak, 2013).
Like other tetracyclines, TGC inhibits bacterial protein synthesis at
the elongation stage by preventing the binding of the ternary complex
amino acid-tRNA·EF-Tu·GTP to the small 30S ribosomal subunit
(Brodersen et al., 2000; Chopra and Roberts, 2001; Pioletti et al., 2001)
due to an overlap in the primary binding site (named Tet-1) with the
position of the anticodon stem loop of the A-site tRNA (Wilson, 2014).
Both tetracycline (TET) and TGC reversibly bind through an Mg2+-
mediated interaction to the Tet-1 site, located in a pocket formed be-
tween helices h34 and h31 (16S rRNA) but in diﬀerent orientations
(Bauer et al., 2004; Grossman, 2016). As compared to classical tetra-
cyclines, TGC has an increased binding aﬃnity that results from a
stacking interaction between the 9-ter-butyl-glycylamido moiety and
nucleotide C1054 in h34 (Jenner et al., 2013; Olson et al., 2006).
Interestingly, glycylcyclines are not or only poorly aﬀected by major
classical TET resistance determinants, i.e. TET-speciﬁc MFS eﬄux
pumps [e.g. Tet(A) and Tet(B) in Gram-negative bacteria; Tet(K) and
Tet(L) in Gram-positives] and ribosomal protection proteins [e.g. Tet
(M) and Tet(O)] (Grossman, 2016; Thaker et al., 2010). This stronger
activity is related to the inhibition of bacterial protein synthesis with a
potency three- and 20-fold greater than those of minocycline and TET
as well as to a binding to 30S and 70S ribosomes with ﬁve- and>100-
fold greater aﬃnity than minocycline and TET, respectively (Bergeron
et al., 1996; Olson et al., 2006; Rasmussen et al., 1994).
Tigecycline: mechanisms of resistance
Clinical resistance to TGC is almost exclusively described in multi-
drug-resistant Gram-negative bacteria, for which this antibiotic has
been used as a last-resort option, usually in combination therapy (Sun
et al., 2013). It commonly results from the overexpression of resistance-
nodulation-cell division (RND) eﬄux pumps, such as AdeABC in A.
baumannii, AcrAB-TolC in K. pneumoniae and Enterobacter spp. or
SdeXY-HasF in Serratia marcescens (Sun et al., 2013). Of note, both P.
aeruginosa and Proteus mirabilis show an intrinsic reduced susceptibility
to TGC associated with the expression of MexXY-OprM and AcrAB-TolC
RND-type systems, respectively (Dean et al., 2003; Visalli et al., 2003).
The role of active eﬄux has also been extensively studied in Gram-
positive S. aureus mutants obtained in vitro, whereas no naturally-oc-
curring clinical isolates with decreased TGC susceptibility have been
reported to date (McAleese et al., 2005). In these in vitro mutants, TGC
resistance was due to overexpression of the mepA gene (coding for an
eﬄux pump belonging to the MATE family) caused by the inactivation
of its transcriptional repressor MepR (Kaatz et al., 2005; Kumaraswami
et al., 2009; McAleese et al., 2005).
In enterococci, the mechanism of TGC decreased susceptibility was
ﬁrst deciphered in E. faecium (Cattoir et al., 2015); resistance is deﬁned
by a MIC > 0.5mg/L (www.eucast.org). TGC resistance determinants
are summarized in Table 2. Mutants with reduced susceptibility to TGC
were obtained in vitro by serial passages using two E. faecium reference
strains, Aus0004 and HM1070 (Cattoir et al., 2015). The derivative
mutants, AusTig and HMtig, exhibited MICs 8-fold higher than those of
the parental strains (0.25mg/L vs. 0.03mg/L, respectively), with a
concomitant 4-to-8-fold increase in MICs of TGC, minocycline and
doxycycline. Importantly, decreased susceptibility was stable over two
weeks without selective pressure, and no decrease in the MIC of TGC
was evident in the presence of eﬄux pump inhibitors such as reserpine
or pantoprazole. In addition, two vanA-positive E. faecium clinical iso-
lates (named EF16 and EF22), collected in 2010 and 2013 in France,
were found to have reduced susceptibility to TGC (Cattoir et al., 2015).
EF16 was positive for tet(M) with a MIC of 0.5mg/L while EF22 har-
bored both tet(M) and tet(L) genes with a MIC of 0.25mg/L. Following a
comparative genomic analysis between AusTig and Aus0004, four dif-
ferent non-synonymous nucleotide mutations were found, including
one in the rpsJ gene, which encodes for the S10 ribosomal protein of the
30S ribosomal subunit. This mutation led to the D60Y substitution (E.
coli numbering), which was also detected in HMtig mutants. A close
mutation in the S10 ribosomal protein (K57E) was also detected in
EF16, whereas no rpsJ mutation was found in EF22.
The role of RpsJ in TGC-reduced susceptibility in E. faecium was
subsequently conﬁrmed (Niebel et al., 2015). In this study, three dif-
ferent pairs of isogenic clinical isolates were characterized, each pair
comprising a susceptible strain before TGC therapy and a non-suscep-
tible strain following TGC exposure. The three pre-treatment strains
(1S, 2S, and 3S) presented MICs of 0.12mg/L, whereas among the post-
exposure isolates, two (1R and 2R) were resistant (MICs of 8mg/L) and
one isolate (3I) showed reduced susceptibility (MIC of 0.5mg/L).
Comparative genomic analysis showed that all modiﬁcations occurred
in a small portion of the S10 ribosomal protein comprised between
positions 52 and 60, including A54E and H56R substitutions in 3I, a
Δ52-56IRATH deletion in 2R and a Δ52I deletion plus Y58H in 1R.
The role of the ribosomal S10 protein as a general target of TGC
Table 2
Overview of acquired mutations/genes possibly contributing to tigecycline resistance in enterococci.
Species Target (gene) Function of target protein Comment Reference
E. faecalis/
E. faecium
RpsJ Ribosomal protein S10
(positions 54-61, E. coli
numbering)
Some mutations are also present in TGC-
susceptible isolates
(Beabout et al., 2015a, b; Cattoir et al., 2015; Fiedler et al.,
2016; Niebel et al., 2015)
Tet(M) Ribosomal protection protein (Beabout et al., 2015b; Fiedler et al., 2016)
Tet(L) MFS-type eﬄux pump (Fiedler et al., 2016)
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insusceptibility was conﬁrmed across several bacterial species. Before
E. faecium, it was ﬁrst described in a KPC-producing K. pneumoniae
clinical isolate, with the description of a substitution V57 L in RpsJ
(Villa et al., 2014). Using an experimental evolution approach, several
strains of A. baumannii, E. faecium, E. coli and S. aureus were adapted to
growth in elevated TGC concentrations (Beabout et al., 2015a). At the
end of the adaptation period, 35 out of 47 replicate populations pre-
sented clones with a mutation in the rpsJ gene. The residues where
mutations in rpsJ were identiﬁed in Gram-positives were at nucleotide
positions 53–56, 58 and 60 while a mutation observed in both Gram-
positive and Gram-negative species was found only at position 57. All
identiﬁed mutations were found on the vertex of an extended loop of
the S10 ribosomal protein (positions 53–60), which is in close proxi-
mity to the 16S rRNA TGC binding pocket (Beabout et al., 2015a). The
mechanism of reduced susceptibility could result from changes in the
conformation or conformational dynamics of 16S rRNA, leading to re-
duced TGC binding aﬃnity and/or a reduction in translational inhibi-
tion by TGC favoring tRNA entry and binding to the ribosome. Of note,
the role of rpsJ mutations was also described in the early steps of TGC
resistance in mutants of Streptococcus pneumoniae obtained in vitro
(Lupien et al., 2015).
A recent study explored the acquisition of TGC resistance in E.
faecalis using an experimental evolution strategy in a bioreactor setup
(Beabout et al., 2015b). In two biological replicates, 24 mutations were
found, but only two candidate loci seemed tightly linked to resistance:
the 5′UTR of the tet(M) gene carried by Tn916 (Δ87-bp and Δ125-bp 51-
bp and 36-bp upstream of tet(M), respectively) and the rpsJ gene (R53Q-
Δ54-57ATHK). In this study, the authors also showed that deletions of
regulatory elements in the 5′UTR of tet(M) led to constitutive over-
expression of tet(M) and a hyper-conjugative phenotype of Tn916. This
study highlights the possibility of rapid spread of a resistance allele
throughout the population.
An increase in TGC-resistant enterococci was reported in Germany
from 2007 to 2015 (n=73 E. faecalis and E. faecium) (Fiedler et al.,
2016). In this study, the authors analyzed three isogenic E. faecium
strains, including the resistant parental strain UW8175 (MIC= 8mg/
L), a susceptible revertant UW8175- (MIC=0.03mg/L) and a high-
level resistant mutant UW8175+ (MIC=64mg/L). By comparative
genomic analysis, they found some diﬀerences with the parental strain:
six SNPs in both UW8175+ and UW8175- mutants, a loss of a 38-kb
plasmid harboring tet(L) and tet(M) in UW8175- and a F62 V substitu-
tion in Tet(L) in UW8175+ . The authors also demonstrated increased
expression of tet(M) and tet(L) (that were co-transcribed) and an in-
creased plasmid copy number of the very same plasmid in UW8175+ as
compared to the parental strain. The putative role of plasmid-associated
tet genes was conﬁrmed with other clinical isolates. Finally, it was also
demonstrated that Tet(M) and Tet(L) were jointly responsible for TGC
resistance in another bacterial host (namely L. monocytogenes EGD-e).
An uncommon mechanism of TGC resistance is provided by enzy-
matic inactivation mediated by the ﬂavin-dependent monooxygenase
Tet(X) (Forsberg et al., 2015). First described in Bacteroides fragilis, then
in environmental and clinical isolates of Enterobacteriaceae and Pseu-
domonadaceae (Grossman, 2016; Moore et al., 2005), it has not been
yet described in Gram-positive bacteria. However, tet(X) has been de-
tected in the human gut microbiota and demonstrated to be harbored
by mobile genetic elements (Aminov, 2013). The overexpression of tet
(X) in E. coli is responsible for a 32-fold increase in the MIC of TGC, and
it has also been predicted that its activity against TGC can be muta-
tionally increased (Grossman, 2016; Linkevicius et al., 2016).
Tigecycline: resistance surveillance data
Recent surveillance and application studies have shown high levels
of TGC susceptibility among Gram-positive clinical isolates worldwide,
with no increase in resistance over time (Hoban et al., 2015; Sader
et al., 2014b). Out of 20,782 enterococcal isolates (14,615 E. faecalis
and 6167 E. faecium) collected globally between 2004 and 2013, 99.7%
were categorized as susceptible according to the CLSI susceptibility
breakpoint (≤0.25mg/L) with a MIC50 of 0.25mg/L (MIC range from
≤0.008 to 1mg/L) (Hoban et al., 2015). Similar rates of< 1% were
reported based on the most recent T.E.S.T. data from Latin America
(Vega and Dowzicky, 2017). TGC susceptibility is not included in EARS-
Net reporting, so available data on resistance to this agent derive from
other sources, studies and surveillance schemes.
In enterococci, only a few TGC non-susceptible clinical isolates have
been initially reported with no characterization regarding the me-
chanism of resistance. This includes one clinical isolate of E. faecalis
(MIC= 2mg/L) recovered in Germany in 2007 (Werner et al., 2008b),
10 clinical and non-clinical isolates (MICs= 0.5–1mg/L) collected in
Portugal between 1999 and 2007, of which seven were E. faecalis, one
E. gallinarum, one E. hirae and one Enterococcus spp. (Freitas et al.,
2011), and one clinical isolate of E. faecalis (MIC=2mg/L) reported in
the UK in 2011 (Cordina et al., 2012).
In Spain, TGC resistance is still sporadic for E. faecalis (0.2%;
range=0.008–2; MIC50= 0.12mg/L and MIC90≤0.25mg/L) and not
reported for E. faecium (range=0.015-0.5; MIC50= 0.06mg/L and
MIC90 ≤0.12mg/L), according to data from the T.E.S.T. survey that
analyzed 1205 E. faecalis and 535 E. faecium isolates collected from 27
medical centers in Spain between 2004 and 2014 (Marco and
Dowzicky, 2016).
In Portugal, data from four major hospitals in the north, center and
south of the country showed the occurrence of two TGC non-susceptible
E. faecalis of ST34 and ST319 from 2002, two from 2015 and two from
2016 [(Freitas et al., 2011); L.P., pers. communication]. In each hos-
pital, the incidence of isolates non-susceptible to TGC was below 1% (L.
P., pers. communication). Data available from T.E.S.T. for TGC and
comparator compounds in Portugal, including 400 isolates from four
centers assessed from 2004 to 2016, showed a single TGC-resistant E.
faecalis isolate (MIC= 1mg/L). Five E. faecalis, one E. gallinarum, one
E. hirae and eight Enterococcus spp. were non-susceptible to TGC
(MIC= 0.5–1.0mg/L), originating from human colonization, chicken
carcasses, piggeries and hospital wastewaters, respectively (Freitas
et al., 2011); https://fenix.tecnico.ulisboa.pt/downloadFile/
1970719973965985/Dissertacao_Ana%20Arronches.pdf).
In Germany, only limited data exist for TGC susceptibility among
clinical enterococcal isolates. As part of the T.E.S.T. surveillance study
(2004–2009) performed in France, Germany, Italy, Spain and the UK,
overall very low resistance rates were reported for E. faecium (2/893;
0.2%) (Aznar et al., 2012). Earlier data for Germany (2004–2007) also
revealed very low TGC resistance rates of< 1% (Seifert and Dowzicky,
2009). A German TGC resistance trial called G-TEST (parts I and II)
ﬂanking the introduction of this antibiotic into clinical practice in
Germany revealed zero (part I) (Kresken et al., 2009) or very low TGC
resistance rates (part II and subsequent years) (Kresken et al., 2011,
2009). However, the German NRC recognized an increasing number of
conﬁrmed TGC-resistant enterococci, mainly E. faecium, in recent years
(unpublished data).
Out of 3974 enterococcal clinical isolates received by the French
NRC from 2006 to 2016, none were categorized as resistant
(MIC > 0.5mg/L), but two isolates (0.05%) exhibited decreased sus-
ceptibility to TGC (MICs=0.25-0.5 mg/L) (Cattoir et al., 2015) (V. C.,
unpublished data).
In Ireland, 560 E. faecium isolates from bloodstream infections
(source: EARS-Net Ireland) were tested against TGC between 2009 and
2016; of these, four were resistant (0.7%). In one institution, TGC re-
sistance was detected in 11 VRE isolates between 2012 and 2017, in one
VR-E. faecalis and ten VR-E. faecium strains. The isolates were cultured
from eight clinical specimens and three screening samples. One TGC-
resistant VR-E. faecium isolate was resistant to LZD as well. Of note,
TGC susceptibility was analyzed using automated testing (VITEK II)
only and resistance was not conﬁrmed by a second independent
method.
TGC resistance was low among enterococcal isolates from
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bloodstream infections reported by the national Italian surveillance
system (AR-ISS). Among the E. faecalis isolates tested in 2015 and 2016,
0.8% (n=9/1,105) and 0.16% (n= 2/1,244) were TGC-resistant, re-
spectively. Corresponding data for E. faecium revealed TGC resistance in
0.4% (n= 2/490; 2015) and 0.3% (n=2/611; 2016).
In Poland, Norway and Denmark TGC-resistant enterococcal isolates
have not been reported to date.
Daptomycin
Daptomycin: mode of action
Daptomycin (DAP) is a cyclic anionic lipopeptide synthesized from
the lipopeptide antibiotic A21978C complex produced by Streptomyces
roseosporus (Debono et al., 1988; Eliopoulos et al., 1985). In 2003, the
USA FDA approved the use of DAP for the treatment of complicated
SSTIs at a dosage of 4mg/kg/day, and later for the treatment of S.
aureus bacteremia with or without right-sided infective endocarditis at
a dosage of 6mg/kg/day (https://www.fda.gov/Drugs/). The EMA
approved DAP for the same indications in January 2006. Treatment
dosage ranges from 4 to 10mg/kg/day. Diﬀerent studies have docu-
mented the safety and tolerability of high-dose daptomycin (8–12mg/
kg/day) (Casapao et al., 2013).
DAP shares structural and functional similarities with cationic an-
timicrobial peptides produced by the mammalian innate immune
system (Jung et al., 2004). The bactericidal eﬀect of DAP involves al-
terations to bacterial cell envelope homeostasis through interactions
with membrane phospholipids; however, this process is not yet fully
understood (Tran et al., 2015). Insertion of DAP into the bacterial cy-
toplasmic membrane is dependent on the divalent cation form of cal-
cium (Ca2+) (Jung et al., 2004; Taylor et al., 2016). In addition, cal-
cium is required for the formation of DAP micellar structures proposed
to facilitate delivery of the antibiotic to the bacterial cytoplasmic
membrane (Ho et al., 2008; Scott et al., 2007; Taylor et al., 2016).
Important steps in the DAP interaction with Gram-positive cell mem-
branes after insertion include oligomerization of DAP-calcium com-
plexes in the outer leaﬂet (Muraih et al., 2012, 2011) and subsequent
translocation of DAP oligomers into the inner leaﬂet of the cell mem-
brane to form functional ring-like pores of two opposing oligomers.
Oligomerization is dependent on interactions with the phospholipid
phosphatidylglycerol (Muraih et al., 2012, 2011), and translocation of
the oligomers is negatively inﬂuenced by the presence of the negatively
charged phospholipid cardiolipin (Zhang et al., 2014b). DAP oligo-
merization is required for its antibacterial activity (Zhang et al., 2013).
DAP pores are cation- and size-selective with greater permeability to
Na+, K+ and other metal cations (Zhang et al., 2014a). The presence of
pores in the membrane presumably results in ion leakage, membrane
depolarization and cell death without lysis (Silverman et al., 2003;
Zhang et al., 2014a).
In addition, DAP induces abnormal septation events (Cotroneo
et al., 2008; Hachmann et al., 2009) and cell wall stress responses
(Muthaiyan et al., 2008), suggesting that this compound causes sig-
niﬁcant cell wall damage. A second explanation for cell death due to the
insertion of DAP into the cell membrane could be that DAP oligomers
induce curved membrane patches (Jung et al., 2008; Pogliano et al.,
2012). These curved patches are then incorrectly identiﬁed by an es-
sential cell division protein as a potential site of division, inducing local
activation of peptidoglycan biosynthesis which causes striking cell wall
and membrane deformities and ﬁnally a rupture in the cell membrane
and cell death (Pogliano et al., 2012).
Chen et al. proposed the extraction of lipids from the cell membrane
as yet another alternative mode of action for DAP (Chen et al., 2014).
They discovered that the interaction between DAP and giant uni-
lamellar vesicles resulted in a lipid extraction eﬀect, i.e. removing lipids
from vesicles. This eﬀect was only observed in the presence of phos-
phatidylglycerol and calcium. However, the authors did not present any
evidence that lipid extraction is required for the antibacterial action of
DAP.
Daptomycin: mechanisms of resistance
Neither the EUCAST nor the CLSI have established (clinical)
breakpoints for DAP resistance in enterococci, but they have set the
epidemiological cut-oﬀ (ECOFF) value for E. faecium and E. faecalis to
≤4 μg/ml for DAP (http://www.eucast.org/ﬁleadmin/src/media/
PDFs/EUCAST_ﬁles/General_documents/EUCAST_daptomycin_
guidance_note_20160924.pdf) (Humphries et al., 2013). Unfortunately,
this value is considered as a clinical breakpoint by some experts (Shukla
et al., 2016). For the purposes of this review, enterococci with DAP
MIC≥ 8 μg/mL will be referred to as “DAP-resistant”.
DAP resistance in enterococci has been associated with distinct
structural alterations to the cell envelope, including increased cell wall
thickening and decreased ability of DAP to alter cell membrane in-
tegrity. Moreover, the development of DAP resistance is associated with
a compelling reduction in cell membrane ﬂuidity and phosphati-
dylglycerol content and an accompanying increase in glycerolphospho-
diglycodiacylglycerol (Arias et al., 2011; Mishra et al., 2012; Steed
et al., 2011). Acquired DAP resistance is associated with mutations in
intrinsic genes (summarized in Table 3). Much of the knowledge re-
garding which mutations are involved in DAP resistance comes from
studies comparing the genomes, membrane potential and cell envelope
composition of susceptible -and resistant more-or less isogenic mutants
developed either in the laboratory or in patients during DAP therapy. In
enterococci, DAP resistance can be linked to mutations in two major
groups of genes, including genes encoding regulatory pathways in-
volved in the coordination of the cell envelope stress response, such as
LiaFSR and YycFGHIJ, and genes encoding enzymes involved in the
metabolism of phospholipids important for cell membrane homeostasis,
such as glycerophosphoryl diester phosphodiesterase (gdpD) and car-
diolipin synthetase (cls) (Arias et al., 2011; Miller et al., 2016; Tran
et al., 2015).
In E. faecalis, initial DAP tolerance is due to the redistribution of cell
membrane cardiolipin-rich microdomains, which diverts DAP from its
preferred binding site at the septum. Tolerance with a MIC close to the
susceptibility breakpoint is associated with mutations within LiaFSR.
High levels of MICs can be reached when additional mutations occur in
gdpD and cls that alter the phospholipid content of the cell membrane
(Arias et al., 2011; Mishra et al., 2012; Munita et al., 2013; Reyes et al.,
2015; Tran et al., 2015, 2013b). A mutation in gdpD does not modify
DAP susceptibility on its own (Arias et al., 2011). In agreement with
this, adaptation of E. faecalis to gradually increasing concentrations of
DAP revealed that the critical ﬁrst step to resistance involves changes in
the LiaFSR pathway. Almost half of the endpoint strains also had a
mutation in cls (Miller et al., 2013).
Mutations in several other genes have been described in DAP-re-
sistant E. faecalis, but further experiments are needed to reveal the exact
function of these genes in E. faecalis and conﬁrm that the mutations are
causatively linked to DAP resistance. Potential resistance mutations
have been reported in genes encoding: 1) GdpP (encoded by yybT), a
cyclic dinucleotide phosphodiesterase associated with the membrane
stress response (Miller et al., 2013; Wang et al., 2017); 2) YvlB, a pu-
tative LiaFSR pathway target protein; 3) GshF, a glutathione synthase;
4) MdpA putative multidrug resistance pump (Miller et al., 2013); 5) a
protein with unknown function containing an HD domain found in an
enzyme superfamily with phosphohydrolase activity, which may be
involved in nucleic acid metabolism and signal transduction; 6) a
membrane protein with a serine incorporator domain that may aid in
serine and phospholipid biosynthesis and promote transport of the
polar serine into the hydrophobic cell membrane; 7) a protein with an
auto-transporter adhesin domain that likely is involved in cell-adhe-
sion; and 8) a membrane protein with an EamA-like transporter family
domain (Palmer et al., 2011).
DAP resistance development seems to be more common in E. fae-
cium than in E. faecalis (Miller et al., 2014). Initial DAP resistance in E.
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faecium is probably due to electrostatic repulsion of the positively
charged DAP-Ca2+ complex from the cell membrane, as seen in S.
aureus and Bacillus subtilis. Resistance is not associated with the redis-
tribution of anionic microdomains as in E. faecalis, although mutations
in liaFSR are the most common changes seen in daptomycin-resistant E.
faecium (Diaz et al., 2014; Tran et al., 2015). Deletion of liaR from
clinical strains harboring mutations in both the LiaFSR and YycFG
pathways reverses DAP resistance and restores the binding of DAP to
the E. faecium cell surface (Panesso et al., 2015). The second most
common modiﬁcations in E. faecium are mutations in YycFG and the
accessory protein YycHIJ, detected in both DAP-resistant and tolerant
isolates. Mutations in cls are further commonly related with DAP re-
sistance in E. faecium, and mutations in gdpD can occasionally be found
(Diaz et al., 2014; Tran et al., 2013a). Cls and YycFG changes only are
probably not suﬃcient to mediate resistance (Diaz et al., 2014; Tran
et al., 2015, 2013a). In E. faecium, mutations in LiaSFR appear before cls
mutations, indicating a sequential progression towards resistance. In-
terestingly, when selective pressure is removed, E. faecium reverts to
become hyper-susceptible through the insertion of IS elements in liaSFR
(Sinel et al., 2016a). There are also several reports of mutations in the
cfa gene encoding a cyclopropane synthase involved in phospholipid
metabolism in E. faecium (Diaz et al., 2014; Tran et al., 2013a; Werth
et al., 2014). The involvement of cfa mutations in resistance is sup-
ported by a signiﬁcant increase in cyclopropane fatty acids in DAP-re-
sistant E. faecium. These fatty acids aid in maintaining the cell mem-
brane in the presence of diﬀerent stressors (Mishra et al., 2012).
Comparing the genomes of DAP-susceptible and DAP-resistant E.
faecium strains has suggested several other mutant genes potentially
associated with DAP resistance, but further functional evidence is
needed to support these genetic ﬁndings. These genes encode: 1) an HD
domain-containing protein also linked to DAP resistance in E. faecalis
(Diaz et al., 2014; Lellek et al., 2015; Tran et al., 2013a); 2) RrmA 23S
rRNA methyltransferase (Diaz et al., 2014; Tran et al., 2013a); 3) the
tellurite resistance protein TelA also linked to DAP resistance in E.
faecalis (Diaz et al., 2014); 4) alpha-mannosidase; 5) alcohol dehy-
drogenase; 6) EzrA, a transmembrane negative regulator of the septa-
tion ring formation protein FtsZ; 7) a protein with unknown function;
and 8) the mannose-speciﬁc IID component of PTS (mannose-speciﬁc
PTS mutations in the IIC and IID domains have been linked to resistance
to class IIa cationic antimicrobial peptide bacteriocins; (Humphries
et al., 2012). Furthermore, whole genome sequencing of isogenic
strains revealed the loss of a 43 kb chromosomal fragment with 42
genes, presumably leading to DAP resistance as no mutations were
observed in genes previously described to confer DAP resistance
(Gumpert et al., manuscript submitted). Altered cell surface charges or
the modiﬁcation of PTS as a receptor are likely to result in DAP re-
sistance in E. faecium (Humphries et al., 2012). A mutation in relA
developed during vancomycin-resistant E. faecium bacteremia in a
leukemia patient caused a constitutively activated stringent response
with elevated baseline levels of the alarmone guanosine tetraphosphate
and tolerance to high doses of both DAP and LZD in a bioﬁlm. This
explained why this infection persisted despite appropriate antibacterial
treatment (Honsa et al., 2017). Analyses of a DAP-resistant E. faecium
that emerged during DAP therapy of endocarditis in a leukemia patient
showed among other mutations alterations in the DNA repair proteins
MutL and RecJ. These changes caused a signiﬁcantly enhanced muta-
tion frequency that possibly contributed to development of high-level
DAP resistance (Matono et al., 2016).
So far, no mutations were identiﬁed in mprF (multiple peptide re-
sistance factor) or the dltABCD operon that could be directly linked to
DAP resistance in enterococci (Arias et al., 2011; Montero et al., 2008).
The examples above demonstrate that changes in many possible
target genes can result in DAP tolerance and resistance and that these
mutations are easily acquired, especially under selective pressure in E.
faecium.
Daptomycin: resistance surveillance data
Most enterococcal isolates (> 99.8%) are susceptible to DAP
worldwide (Sader et al., 2014a), and this trend did not change in
European and US hospitals in the period from 2009 to 2013 (Sader
et al., 2015). The occurrence of DAP-resistant enterococci is most often
associated with prior DAP exposure (DiPippo et al., 2016; Lellek et al.,
2015; Lewis et al., 2016) and may correspond to the use of too low
dosages of DAP not providing high enough plasma concentrations to kill
enterococci (Hall et al., 2012; Sinel et al., 2016b; Werth et al., 2014). A
recent study provided evidence of the frequent in vitro increase of MIC
values to DAP among E. faecalis strains highly resistant to gentamicin
(Pericas et al., 2017). The results suggest the convenience of testing the
MIC values of combination compounds in the presence of subinhibitory
concentrations of DAP to predict the eﬃcacy of combination therapy
for multidrug resistant enterococci (e.g. DAP plus ampicillin). When
DAP is used in combination with other antibiotics, the possibility of
selecting MDR phenotypes might be increased (Cercenado and Pachon,
2012). DAP susceptibility data for enterococci cannot be included in
EARS-Net data (due to a missing EUCAST breakpoint), so resistance
data are derived from other sources, studies and surveillance schemes.
Although in vitro resistance arises spontaneously at low frequencies,
the emergence of resistance is increasingly selected during DAP
therapy. It could be related to the mutant selection window (MSW),
which lies between the MIC and the mutant prevention concentration
(MPC) and corresponds to the concentration range within which re-
sistant mutants may be selected. Indeed, it has been shown that free
Cmax (taking into account the protein binding of DAP, approx. 90%)
values for DAP usually fell into the MSW when using low dosages
(4–6mg/kg), thus suggesting a risk of in vivo selection of resistant
mutants, especially at sites of infection where the concentration of DAP
is low (Sinel et al., 2016b). Therefore, high daily doses of DAP
(≥10mg/kg) may be considered for the treatment of infections due to
E. faecium.
The transmission of DAP- and vancomycin-resistant enterococci
within the hospital environment has been documented (Lellek et al.,
2015). Moreover, population genetics assessing DAP-resistant E. fae-
cium from a medical center in New York showed that a novel clone,
ST736, was associated with resistance in this region (Wang et al.,
2014).
The European Cubicin Outcomes Registry and Experience (EU-
CORE) had been introduced as a retrospective, European, post-mar-
keting, non-interventional registry of DAP use in patients who received
at least one DAP dose. The database provides information from 6075
patients representing 18 countries and 314 study sites. The primary
objective was to evaluate the clinical outcomes of patients treated with
this drug (Cogo et al., 2015; Gonzalez-Ruiz et al., 2015).
In Spain, DAP is mostly used as a rescue therapy, at 6mg/kg/day, in
both hospitalized and non-hospitalized patients according to data from
the EU-CORE database (Spain, with 47 hospitals, is the best represented
country in this database) (Cercenado and Pachon, 2012; Sandoval et al.,
2015). The ﬁrst DAP-resistant enterococcal isolate in Spain was an
ST117 E. faecium strain (MIC= 12mg/L) recovered from a 46-year-old
woman following kidney transplantation in 2005. The isolate showed a
novel substitution in the response regulator LiaR and also harbored a
change in the active site of the cardiolipin synthase (Sorlozano et al.,
2015). The proportions of DAP-resistant E. faecalis and E. faecium are
3.23% and 10.53%, respectively, according to a national collaborative
study performed in Spain (M. Palomar, unpublished data). The me-
chanisms of resistance were not explored in this study.
In France, a recent increase in the MIC of DAP in E. faecium has been
observed, particularly in the proportion of strains with MICs> 4mg/L
(6–12mg/L): 0% for the period 2006–2013, 1.1% (3/267) in 2014,
7.0% (24/344) in 2015 and 8.2% (31/379) in 2016.
In Ireland, among 60 E. faecium isolates from bloodstream infections
(source: EARS-Net Ireland) tested against DAP between 2009 and 2014,
four were resistant (7%). A tertiary care referral center has detected 12
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DAP-resistant E. faecium isolates since 2016; six E. faecium isolates were
sensitive to vancomycin and resistant to DAP, the other six isolates were
VR-E. faecium resistant to DAP. All isolates were susceptible to LZD and
TGC. One patient who had received a lengthy course of DAP while in
the ICU was found to carry VR-E. faecium resistant to DAP both in the
intra-abdominal drain ﬂuid and blood culture. All DAP-resistant isolates
were grown from clinical specimens (six blood cultures, one wound
swab and ﬁve drain ﬂuids).
Data on DAP susceptibility in clinical enterococci in Italy is limited,
as only one laboratory tests and reports data from enterococcal bac-
teremia to the national Italian surveillance system (AR-ISS). In 2015
and 2016, a total of 181 isolates were tested, of which 125 were E.
faecalis, with two that were DAP-resistant. Of 56 E. faecium isolates,
none were DAP-resistant.
In Denmark, DAP-resistant enterococci are not sent to the anti-
microbial reference laboratory on a routine basis. However, during
2017, resistance to DAP was detected in two E. faecalis strains and one
E. faecium isolate at Rigshospitalet, Denmark (H.W. and J. D. Knudsen,
pers. communication).
In Germany, DAP-resistant enterococci are sent to the reference
centre on a voluntary basis. During recent years, resistance to DAP was
conﬁrmed for a few E. faecalis and E. faecium isolates per year only,
performed and analysed by two independent methods (broth micro-
dilution and Etest®; J.B. and G.W. unpublished data).
No DAP-resistant enterococcal isolates have been noted in Poland,
Norway and Portugal so far.
Individual resistance development under therapy and subsequent
transmission of successful DAP-resistant clones warrant careful sur-
veillance of these isolates in order to prevent their wider spread and to
keep DAP as a valuable therapeutic alternative.
Conclusions and proposal for a common nomenclature
The review summarizes the current knowledge on mechanisms of
resistance to the last-resort antibiotics linezolid, tigecycline and dap-
tomycin in Enterococcus spp., and where available provides relevant
surveillance data, partly unpublished, for many European countries.
We advocate using a suitable method for conﬁrmation of these re-
sistances, such as the broth dilution assay, and additionally recommend
submitting relevant strains to reference laboratories for external con-
ﬁrmation, to support their reference and alert functions and to elucidate
the corresponding resistance mechanisms. Using a common and agreed-
upon standard is essential and available for Europe using the EUCAST
methodology, clinical breakpoints and guidelines (www.eucast.org).
What has been causally indicative for VRE prediction on the basis of
the presence of vanA or vanB genes is far from easy for the resistance
phenotypes discussed in this review, which in turn require more so-
phisticated conﬁrmatory assays based on whole genome sequence
(WGS) data, as well as sophisticated transcriptomic and genetic ana-
lyses. Loss of susceptibility to linezolid, tigecycline and daptomycin in
enterococci may be associated with a variety of resistance mechanisms
(target mutations, gene acquisitions, “gene dosage eﬀects” and many
others); a number of them also appear in a combined fashion. Resolving
complex resistance mechanisms requires high throughput data entering
and hypothesis-free approaches, thus allowing an “open view” (Chacko
et al., 2018). Considering this potential complexity, extracting a clinical
breakpoint (an MIC) for linezolid, tigecycline and daptomycin for En-
terococcus isolates or predicting potential therapeutic success from WGS
data seems challenging and, at present, requires additional and com-
prehensive isolate collections and more dedicated studies to support
this concept. Genome-wide association studies will potentially pave the
way towards the better prediction of resistance phenotypes out of
multiple genome comparisons (Power et al., 2017).
Resistance to last-resort antibiotics in enterococci which, in general,
serve as important indicator bacteria, requires contemporaneous and
strict surveillance to detect the emergence and dissemination of these
important resistance mechanisms. With this review, we also propose a
common nomenclature for VRE additionally exhibiting these resistance
phenotypes (Table 4).
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